Search
Search Results
-
The Dependence of the Electrophysiological Effects of Class III Antiarrhythmic Drug Refralon on the Frequency of Myocardium Activation
We studied the frequency dependence of the effects of the novel Russian class III antiarrhythmic drug refralon on the duration of action potentials...
-
Characterization of hERG K+ channel inhibition by the new class III antiarrhythmic drug cavutilide
Cavutilide (niferidil, refralon) is a new class III antiarrhythmic drug which effectively terminates persistent atrial fibrillation (AF; 84.6% of...
-
K Channel Openers as New Antiarrhythmic Agents
Cardiac cation channels are membrane proteins that provide controlled ion passage through cellular membranes to allow electrical control of the...
-
Kv11.1 (hERG1) Channels and Cardiac Arrhythmia
The rapid delayed rectifier K+ current (IKr) is one of several outward currents that mediate repolarization of cardiac action potentials in humans...
-
-
Long-term in vitro recording of cardiac action potentials on microelectrode arrays for chronic cardiotoxicity assessment
The reliable identification of chronic cardiotoxic effects in in vitro screenings is fundamental for filtering out toxic molecular entities before in...
-
Therapeutic advances in atrial fibrillation based on animal models
Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia among humans, with its incidence increasing significantly with age....
-
Human-Induced Pluripotent Stem Cell-Based Differentiation of Cardiomyocyte Subtypes for Drug Discovery and Cell Therapy
Drug attrition rates have increased over the past few years, accompanied with growing costs for the pharmaceutical industry and consumers. Lack of in...
-
Environmental Signals
Environmental factors have long been known to play a role in the pathogenesis of congenital heart disease (CHD), but this has not been a major focus...
-
Disease Models in Safety Pharmacology
The discipline of safety pharmacology can impact all stages of drug discovery and development from early target identification to regulatory...
-
Cardiac Na+/Ca2+ exchange stimulators among cardioprotective drugs
We previously reviewed our study of the pharmacological properties of cardiac Na + /Ca 2+ exchange (NCX1) inhibitors among cardioprotective drugs, such...
-
New Antiretroviral Agents for HIV Infection
The development of antiretroviral drugs for treatment of human immunodeficiency virus (HIV) infection is the most remarkable achievement in medical...
-
Drugs Used in Cardiac Arrhythmias
Cardiac arrhythmias range from the fast-beating tachyarrhythmias–which include atrial fibrillation, ventricular tachycardia, and fibrillation and the...
-
Sex Differences in Pharmacokinetics
Because women have been excluded from most clinical trials, assessment of sex differences in pharmacokinetics is available for a minority of...
-
Cardiac hERG K+ Channel as Safety and Pharmacological Target
The human ether-á-go-go related gene (hERG, KCNH2) encodes the pore-forming subunit of the potassium channel responsible for a fast component of the...
-
QTc Prolongation in Poison Center Exposures to CredibleMeds List of Substances with “Known Risk of Torsades de Pointes”
Many drugs carry some risk of QT interval prolongation, which can lead to life-threatening dysrhythmias including Torsades de Pointes (TdP)....
-
-
-
Ion Channels as Drug Targets in Atrial Fibrillation
Atrial fibrillation is triggered when an abnormal electrical impulse encounters a substrate that allows initiation of re-entry. The arrhythmia has a...
-
A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
Integrase strand transfer inhibitors (INSTIs) have improved the treatment of human immunodeficiency virus (HIV). There are currently four approved...
